Arthritis drugs already available for prescription have the potential to halt lingering lung problems that can last months or years after COVID-19 infections, new research from the University of Virginia School of Medicine and Cedars-Sinai suggests.
Centessa 2.0 with a twist: Medicxi combines six immuno-derm startups with $100M
European biotech investor Medicxi is bringing six startups under one roof to form an immuno-dermatology drugmaker with 14 pipeline projects in a move reminiscent of